ALFA Finder| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | Guided 25% growth for the current fiscal year. |
|---|---|
| Margins | Targeting 24-25% EBITDA margins; 60-63% gross margins standard. |
| Order book | 2-year rate contract for TB with Government of India just signed. |
| Demand visibility | Strong for TB; expanding into HPV and European STI markets. |
| Management confidence | High; citing proprietary technology and recurring kit revenue (75% of total). |
Growth
Revenue ₹408 Cr, EBITDA ₹104 Cr (25% margin), PAT ₹52.7 Cr (13% margin). Sold 164 devices and 62.4 lakh kits.
Outlook
Guided 25% Revenue growth and 24-25% EBITDA margins for FY27. ₹72 Cr capex for automation; ₹105 Cr for Bangalore R&D center.
Risks
Non-linear quarterly public health business; OptraScan expected to remain loss-making in FY27.
Earnings Call Transcript filed with BSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,493.20
- Market cap
- ₹17,208 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- P/E (TTM)
- 111.5×Sector 55.1×
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Earnings Call Transcript: Key Takeaways
H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.
- Call
- Guides 25% growth
Molbio Diagnostics Other Announcement
Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.
Molbio Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.
- Call
- Guides 25% growth
Molbio Diagnostics Q2 FY27 Results: Net Profit ₹7.7 Cr, Down 92.8% YoY
Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.7 Cr · -92.8% YoY
Molbio Diagnostics Board Meeting Date
Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.
Molbio Diagnostics Price Movement Clarification
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.